Complete Guide to Rifaximin Impurity Reference Standards: Analysis of Eight EP Impurities + Consistency Evaluation Stocking List
1. Rifaximin: A Gut-Selective Antibacterial Agent — Why Its Impurity Control Is Especially Complex
Rifaximinis a semisynthetic derivative of rifamycin SV, first approved for marketing in Italy in 1988 under the trade name Xifaxan. Its core pharmacological feature is that it is almost not absorbed from the gut after oral administration (absorption rate <0.4%), exerting broad-spectrum antibacterial activity locally in the intestinal lumen by irreversibly binding to the β subunit of bacterial DNA-dependent RNA polymerase to inhibit bacterial RNA synthesis. Current main indications include traveler's diarrhea, diarrhea-predominant irritable bowel syndrome (IBS-D), and hepatic encephalopathy (HE).
Rifaximin
CAS No.:80621-81-4
Domestically, multiple companies already hold old marketing approvals for rifaximin tablets, but as of 2026, no generic has yet passed consistency evaluation; generic market share is less than 1%, and the originator product still dominates. As the market continues to grow (about 26% growth over the past 5 years) and the crystal form barrier (the α crystal form is the key form of the marketed formulation) gradually gains attention, more generic companies are expected to advance consistency evaluation studies.
Rifaximin impurity control is more difficult than for ordinary chemically synthesized drugs because it is produced by a combined microbial fermentation-semisynthesis process. Fermentation intermediates such as rifamycin O have complex structures, and the process impurities introduced in the synthesis steps, structurally similar isomers, and multiple degradation pathways together constitute a large and complex impurity profile, placing extremely high demands on reference standard support.
2. Classification of Rifaximin Impurity Sources
Understanding the impurity sources of rifaximin helps researchers accurately select the required reference standard types:
Process impurities:derived from starting materials (such as rifamycin S), intermediates, and side-reaction products in the synthetic route. These impurities are structurally similar to the rifaximin main body, with molecular weights usually in the 750–810 Da range, and are the key controlled items in the EP pharmacopoeia.
Degradation impurities:rifaximin is sensitive to alkaline and oxidative conditions; in forced degradation studies, degradation is most significant under alkaline conditions, followed by oxidative degradation. Representative degradation impurities include two oxidative degradation products, both with structural identification data reported in the literature.
Starting material-related impurities:rifamycin S (Rifamycin S) is the key starting material for rifaximin synthesis and is also EP Impurity E listed in the European Pharmacopoeia, with dual significance in API quality studies.
Metabolic/ADME-related compounds:rifaximin has extremely low oral absorption and limited systemic metabolism. The N-oxide (rifaximin imine-N-oxide, CAS 51963-55-4) is a reported metabolism-related compound with application value in ADME and metabolite identification studies.
Isotope-labeled compounds:rifaximin-d6 (CAS 1262992-43-7) is a deuterated isotope-labeled internal standard used mainly for quantitative analysis of biological samples by LC-MS/MS, playing a key role in ADME studies and bioequivalence testing.
3. Eight Impurities Listed in the European Pharmacopoeia (EP)
The European Pharmacopoeia (Ph. Eur.) lists eight controlled impurities from A to H for rifaximin (consecutively named, with no skipped letters), with reversed-phase HPLC as the core analytical method at a detection wavelength of 276 nm, and Impurity D and Impurity H as system suitability markers (both with relative retention times (RRT) of about 0.7).
Notably:Impurity A (2-amino-4-methylpyridine, MW 108) is a small-molecule synthetic intermediate whose chromatographic behavior differs significantly from the other seven large-molecule impurities of the rifamycin skeleton; special attention should be paid to the compatibility of detection conditions during method development. The structural identification of Impurity H has an academic history — the structure assigned in early EP versions was found to be incorrect, and was corrected after re-identification by NMR/MS by Stradi et al. in 2010; the currently listed structure is a hydroxymethyl derivative demethylated at position 16.
*CATO can currently provide the complete eight-item set of rifaximin EP Impurities A through H, with Impurity H (CP107013) and rifamycin S (i.e., EP Impurity E, CCAD302181) available from stock. All items have undergone multiple characterizations including HPLC, NMR, and MS, with the COA containing an uncertainty statement (±2.0%, 95% CI), meeting regulatory filing requirements. CATO is currently one of the domestic reference material suppliers holding dual ISO 17034 certification with CNAS RM0030 and ANAB AR-2832, and can issue value-assigned reference standards within the dual accreditation scope.
4. Naming Correspondence Between the Chinese Pharmacopoeia (ChP) and the EP: A Misconception That Must Be Clarified
Many QC personnel, when using domestic testing standards, tend to confuse "Impurity A" in the ChP with "Impurity A" in the EP — these are two completely independent naming systems, and impurities with the same name are not the same compounds.
The related substances test method for rifaximin in the Chinese Pharmacopoeia uses octylsilane-bonded silica as the stationary phase, a methanol-acetonitrile-phosphate buffer system as the mobile phase, and a detection wavelength of 240 nm; in the system suitability solution, peaks elute in the order of Impurity A, rifaximin, and Impurity B (i.e., ChP Impurity A elutes before the main peak, and the relative retention time of Impurity B is about 4).
In contrast, the EP analytical method uses an amide-end-capped ODS column, an ammonium formate-ammonia buffer system (pH 7.2) with an acetonitrile-methanol mixed organic phase, a detection wavelength of 276 nm, and Impurity D and H as system suitability markers (RRT ≈ 0.7, both eluting before the main peak).
The two methods have different chromatographic systems, mobile phases, pH values, and detection wavelengths, so the corresponding "Impurity A" is naturally not the same compound. If the impurities of the two pharmacopoeias need to be correlated in the filing documents, the assignment should be based on the CAS number or structural formula of each impurity, not merely on letter naming.
5. Complete Stocking List for Consistency Evaluation
For generic companies advancing or planning to advance rifaximin consistency evaluation, the following is the recommended impurity reference standard list, covering various application scenarios including method development, impurity studies, stability investigation, and LC-MS analysis:
CATO covers all 14 items above, with the complete eight-item EP Impurities A–H set configurable; in-stock items can be delivered quickly, and non-stock items can be custom synthesized — delivery times are subject to the latest inventory status.
Scan the code to add CATO WeCom
For more rifaximin product details, please contact CATO
Frequently Asked Questions (FAQ)
Q1: EP Impurity D has no public CAS number; how can I confirm that the purchased reference standard has a consistent structure?
A: No publicly registered CAS number is currently available for Impurity D, which is not uncommon for complex impurities of biosynthetic origin. When evaluating reference standard quality, you should require the supplier to provide multi-dimensional structural characterization data such as ¹H NMR, ¹³C NMR, and high-resolution mass spectrometry (HRMS), and verify them against the structural formula in the EP monograph. The COA should include HPLC purity (≥95%) and uncertainty data.
Q2: Is it necessary to stock all EP impurity reference standards for consistency evaluation?
A: The necessary scope should be determined based on the actual process route and impurity risk assessment results; it is not mechanically required to stock every EP impurity one by one. However, EP Impurities D and H, as the essential standards for method system suitability verification, together with the impurity reference standards related to your own process, are the basic configuration for method development and QC release. It is recommended to determine the complete stocking plan in accordance with ICH Q3A, combined with impurity identification and limit requirements.
Q3: Does rifaximin have any genotoxic impurity (GTI) risk?
A: No ICH M7-specific genotoxicity concern notice for rifaximin or its process impurities has been seen in the current public literature or regulatory documents. Among the eight EP-listed impurities, Impurity A (2-amino-4-methylpyridine) is a small molecule containing an amino group; from a structural alert perspective, companies usually conduct a GTI assessment on it during the process research stage. It is recommended to conduct the assessment using (Q)SAR prediction tools and literature review to improve the risk control documentation.
Q4: How does the rifaximin crystal form affect consistency evaluation?
A: Rifaximin has five crystal forms — α, β, γ, δ, and ε. The originator product uses the α form, with extremely low oral absorption (about 0.4%) and reliable local intestinal delivery. Different crystal forms have significantly different pharmacological properties; generic research must ensure the same α form as the originator, which is also one of the key technical difficulties in the consistency evaluation of this product.
Rifaximin has a complex impurity profile, many types of reference standards, incompatible EP and ChP naming systems, plus the requirements for crystal form research and systematic coverage of related impurities, making complete reference standard stocking difficult domestically in the long term.
CATO can currently provide the complete eight-item set of rifaximin EP Impurities A–H, as well as 14 related items including isotope internal standards and metabolic impurities. Products are characterized by HPLC+NMR+MS triple characterization, with purity ≥95%, COA containing uncertainty statements, and dual ISO 17034 certification with CNAS RM0030 and ANAB AR-2832, supporting traceability of filing documents. To obtain specific inventory status, COA samples, or custom synthesis quotations, please contact the CATO technical service team.
References
[1] Marchi E, Mascellani G, Montecchi L, et al. 4-Deoxypyrido[1′,2′:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J Med Chem, 1985, 28(7): 960–963.
[2] Hepatox Drug-Induced Liver Injury Professional Website. Rifaximin drug information. http://www.hepatox.org/drug/show/379
[3]Baidu Baike. Rifaximin entry (citing Chinese Pharmacopoeia-related content). https://baike.baidu.com/item/利福昔明/7063208
[4] European Pharmacopoeia (Ph. Eur.) 10.0. Monograph: Rifaximin. European Directorate for the Quality of Medicines & HealthCare (EDQM). Available cited source: https://www.bocsci.com/product/rifaximin-impurity-d-479076.html
[5] Stradi R, Nava D, Nebuloni M, et al. Structural elucidation of the rifaximin Ph. Eur. impurity H. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51(4): 858–865. DOI: 10.1016/j.jpba.2009.10.010. PMID: 19926422.
[6] Liu C, Hu CQ, Jin SH. Structure Elucidation of Two Unknown Oxydic Degradation Impurities of Rifaximin. Asian Journal of Chemistry, 2011, 23(7): 3252.
[7]BOC Sciences. Rifaximin EP Impurity A (CAS 695-34-1). https://www.bocsci.com/product/rifaximin-ep-impurity-a-cas-695-34-1-325553.html
[8] BOC Sciences. Rifaximin EP Impurity H (CAS 1210022-90-4). https://www.bocsci.com/product/rifaximin-ep-impurity-h-cas-1210022-90-4-479077.html
[9] BOC Sciences. Rifaximin EP Impurity E / Rifamycin S (CAS 13553-79-2). https://www.bocsci.com/product/rifaximin-ep-impurity-e-cas-13553-79-2-57816.html
[10] Mengent Pharmaceutical (formerly Pharmcloud). Reviewing three blockbuster small-molecule drugs with expiring patents: linagliptin tablets, rifaximin tablets, and dasatinib tablets. https://www.pharnexcloud.com/zixun/sd_36251
[11] Mengent Pharmaceutical (formerly Pharmcloud). Five blockbuster small-molecule drugs with expiring patents: how is the domestic generic "battle" going? https://www.pharnexcloud.com/zixun/sd_36253
[12] ICH Q3A(R2). Impurities in New Drug Substances. International Council for Harmonisation, 2006.
[13] ICH M7(R2). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. ICH, 2023.